Fennec (NASDAQ: FENC) Chief Strategy Officer receives 156-share stock award

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported a routine equity compensation event. She acquired 156 common shares at no cost in a grant or award transaction, bringing her direct holdings to 24,332 common shares. The shares represent a release from restrictions on stock previously awarded on March 28, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cioffi Christiana Marie

Role Chief Strategy Officer

Type	Security	Shares	Price	Value
Grant/Award	Common shares	156	$0.00	--

Holdings After Transaction: Common shares — 24,332 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 156 common shares Price per share: $0.00 per share Post-transaction holdings: 24,332 common shares +1 more

4 metrics

Shares acquired 156 common shares Award reported on June 30, 2026

Price per share $0.00 per share Grant, award, or other acquisition

Post-transaction holdings 24,332 common shares Direct ownership after transaction

Award grant date reference March 28, 2025 Original award from which shares were released

Key Terms

Common shares, Grant, award, or other acquisition, shares released from restriction

3 terms

Common shares financial

"security_title: "Common shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:34 PM Accepted by SEC EDGAR 07/01/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cioffi Christiana Marie

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	06/30/2026		A		156	A	$0	24,332	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Christiana Cioffi	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did FENC Chief Strategy Officer report on this Form 4?

FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported acquiring 156 common shares through an equity award. The shares were received at no cost as part of a grant, increasing her direct holdings to 24,332 common shares.

Was the FENC insider transaction a market purchase or sale?

The transaction was not a market purchase or sale. It was classified as a grant, award, or other acquisition of 156 common shares at a price of $0.00 per share, reflecting routine equity compensation rather than open-market trading.

How many FENC shares does the Chief Strategy Officer hold after this transaction?

After receiving 156 additional common shares, Christiana Marie Cioffi holds 24,332 FENNEC PHARMACEUTICALS INC. common shares directly. This total reflects her position following the reported award-related share release on June 30, 2026.

What is the origin of the 156 FENC shares acquired in this Form 4 filing?

The 156 common shares represent a release from restriction on shares previously awarded on March 28, 2025. This means restricted stock granted earlier became freely vested and was reported as an acquisition in the Form 4 filing.

Does the FENC Form 4 indicate any derivative securities or option exercises?

The Form 4 data shows no derivative security transactions or option exercises. The filing only reports a non-derivative acquisition of 156 common shares through an award, with no derivative positions listed in the derivative summary.